DEF 14A: Acurx Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting

Acurx Pharmaceuticals announces its 2024 annual meeting of stockholders to be held virtually on June 17, 2024, focusing on director elections and auditor ratification.

Summary

• Acurx Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on June 17, 2024, at 10:00 a.m. EST.
• Stockholders will elect three Class III directors to serve three-year terms expiring in 2027.
• The meeting will also include a vote to ratify the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board of directors recommends voting in favor of the director nominees and the ratification of the accounting firm.
• The record date for determining stockholders eligible to vote is April 26, 2024.
• The company intends to begin sending the Notice of Internet Availability of Proxy Materials on or about May 2, 2024.
• Stockholders can attend, vote, and submit questions during the virtual meeting at www.virtualshareholdermeeting.com/ACXP2024.
• The company has engaged Broadridge Investor Solutions, LLC to act as its proxy solicitor, with a fee of approximately $15,000 plus expenses.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the expression of gratitude for stockholder support and the anticipation of the annual meeting.

Positives

• The virtual format of the annual meeting is expected to improve stockholder attendance and participation while reducing costs and environmental impact.
• The board of directors is actively engaged in risk oversight and has established committees to manage various aspects of the company's operations.
• The company has a code of conduct and ethics in place for all employees, including executive officers.
• The company has engaged Pearl Meyer & Partners, LLC as an independent compensation consultant.

Negatives

• The company has chosen to explain why it does not meet the diversity objectives of Nasdaq Rule 5605(f)(2)(C).
• Form 4 reports, covering an aggregate of three (3) transactions, were filed late by Robert J. DeLuccia, Robert G. Shawah and David P. Luci.

Risks

• The proxy statement mentions the ongoing need to manage risks inherent in the operation of the business and the implementation of business strategies.
• The company's success depends on the election of qualified directors and the ratification of a competent independent accounting firm.
• Failure to comply with Section 16(a) of the Exchange Act could result in penalties.

Future Outlook

The document outlines the business to be conducted at the annual meeting and provides information for stockholders to make informed decisions regarding voting.

Management Comments

• David P. Luci, President & Chief Executive Officer: 'Thank you for your continued support of Acurx. We look forward to seeing you at the annual meeting.'

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, election of directors, and ratification of auditors.

Comparison to Industry Standards

• Holding a virtual annual meeting is becoming increasingly common among publicly traded companies to enhance accessibility and reduce costs, similar to practices adopted by companies like Pfizer and Johnson & Johnson.
• The structure of the board of directors, with independent directors and committees, aligns with best practices in corporate governance, as seen in companies like Merck and AbbVie.
• The engagement of an independent compensation consultant, such as Pearl Meyer, is a standard practice to ensure fair and competitive executive compensation, similar to practices at Amgen and Gilead Sciences.

Related Party Transactions

• The document mentions investor rights agreements with certain stockholders, including directors and executive officers.
• It also discusses indemnification agreements with directors and executive officers.
• Participation in Our Registered Direct Offering and Concurrent Private Placement in July 2022.

Stakeholder Impact

• The document informs stockholders about important matters to be voted on at the annual meeting.
• The virtual meeting format aims to enhance accessibility for all stockholders.
• The election of directors and ratification of the auditor impact the company's governance and financial oversight.

Next Steps

• Stockholders are encouraged to vote promptly via the Internet, telephone, or mail.
• Stockholders can attend the virtual annual meeting on June 17, 2024, to participate and vote.
• The company will announce preliminary voting results at the annual meeting and publish final results in a Form 8-K.

Key Dates

Keywords

annual meeting, proxy statement, directors, stockholders, CohnReznick LLP, corporate governance, executive compensation, Acurx Pharmaceuticals